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Abstract Postmenopausal women with severe osteoporosis
may require treatment with the bone anabolic drug
teriparatide. While changes in bone mineral density (BMD)
are one measure of response, BMD changes often require a
minimum of one year to observe measureable changes. Bio-
chemical markers of bone turnover change within 1 to
3 months of initiating osteoporosis therapy. Monitoring with
a marker such as procollagen type I N propeptide (PINP), an
osteoblast-derived protein, during teriparatide treatment may
provide clinically useful information for managing patients
with osteoporosis. Clinical trials have shown consistent in-
creases in PINP within 3 months of initiating teriparatide,
increases that are significantly greater than placebo and
significantly different from baseline. Increases in PINP
concentrations during teriparatide treatment correlate well
with increases in skeletal activity assessed by radioisotope
bone scans and quantitative bone histomorphometry pa-
rameters. Individuals treated with teriparatide in clinical
trials usually experienced an increase in PINP > 10mcg/L from
baseline, while those given placebo usually did not. In the
clinical setting, patients experiencing a significant increase in
PINP > 10 mcg/L after initiating teriparatide therapy may
receive an earlier confirmation of anabolic effect, while those
who do not may be assessed for adherence, proper injection
technique, or undetected secondary conditions that might mit-
igate an anabolic response. PINP monitoring may provide
information supplemental to BMD monitoring and be a useful
aid in managing patients receiving anabolic osteoporosis treat-
ment in the same way that biochemical markers of bone re-
sorption are useful in monitoring antiresorptive therapy. This
review examines PINP as a biological response marker during
teriparatide treatment for osteoporosis.
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Introduction
Patients with osteoporotic fractures may be asymptomatic and
yet have significant skeletal deterioration and high risk for
future fractures. In such patients, teriparatide has the potential
to increase bone formation on bone surfaces, increase bone
mineral density (BMD), increase bone strength, and reduce
the risk of vertebral and nonvertebral fractures [1–7].
After a patient is prescribed teriparatide, initiating and
continuing treatment to obtain a biological response requires
several steps: (1) the patient must acquire the medication and
supplies for subcutaneous (SC) injections; (2) the patient must
refrigerate the medication at 2–8°C to retain its stability [8];
(3) the patient must self-administer teriparatide properly by
daily SC injection or make arrangements for a trained care-
giver to administer the injection [8]; (4) the patient must not
have medical conditions that preclude an anabolic response
[8]; and (5) the patient must persist with treatment to achieve
the desired response. Assessing all these steps through a
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detailed patient interview might be difficult to accomplish. In
addition, prescribers may overestimate their patients’ adher-
ence to treatment. For example, Curtis and colleagues [9]
reported physicians estimated 67.2 % of their osteoporosis
patients to be adherent, while only 40 % of patients were
actually adherent based on pharmacy data.
Concurrent monitoring for a biological response to
teriparatide may provide useful clinical information for the
prescriber and for the patient with osteoporosis at high risk for
fracture. However, BMD testing is typically not obtained until
after 1 to 2 years of treatment [10, 11]. This delay in assessing
for biological response may be problematic in light of a need
for bone formation in patients at high risk for fracture and a 2-
year lifetime exposure limitation to teriparatide [8]. Accord-
ingly, a biological response marker measureable earlier than
BMD may be useful to more proactively manage patients
treated with teriparatide.
Biochemical markers of bone turnover have the potential to
provide early feedback to patients and prescribers during
osteoporosis treatments [12–14]. For example, patients treated
with teriparatide exhibiting a positive biochemical marker
response can receive confirmation of an anabolic biologic
response in the bone. This may be especially important since
overall patient compliance with osteoporosis treatments is
inadequate and could be enhanced by the assurance of a
positive biological response to the medication [15]. In fact,
the International Osteoporosis Foundation (IOF) determined
the most common factor women cite for persisting with their
osteoporosis treatment: “knowing I’m doing something to
help” [16]. On the other hand, patients without a signif-
icant change in biochemical marker concentration during
teriparatide treatment can be assessed for difficulties
with injection technique, medication storage, adherence,
or for conditions that might impair response to therapy.
If problems are identified, addressed, and corrected, this
type of early assessment has the potential to improve
patient outcome [17].
Several biochemical markers of bone formation may be
measured in the serum: osteocalcin, bone-specific alkaline
phosphatase (bone ALP), procollagen type I N propeptide
(PINP), and procollagen type I C propeptide (PICP) [12, 14,
18]. Because type I collagen is the most prevalent protein in
bone, measuring byproducts of collagen synthesis is an ap-
pealing approach. Following the synthesis of new type I
collagen within the osteoblast, PINP is cleaved from type I
procollagen by proteases outside the osteoblast (Fig. 1) [12,
18]. Serum PINP concentrations reflect the integrated amount
of skeletal new bone formation [19]. Thus, diseases involving
high bone turnover would be expected to be associated with
high serum concentrations of PINP; examples are metabolic
bone diseases including osteomalacia and Paget’s disease,
endocrine disorders including thyrotoxicosis and primary hy-
perparathyroidism, and malignant bone disease such as
multiple myeloma [12]. Importantly, the label warns against
the use of teriparatide in patients with these diseases [8].
While PINP primarily originates from bone, small amounts
of type I collagen, and hence PINP, are contributed from other
tissues such as skin, tendon, dentin, ligaments, cartilage, and
interstitial tissues [14, 20]. For example, the acute
fibroproliferative reaction in a healing wound is associated
with increased concentrations of PINP in the extra-cellular
fluid of the wound [21].
Serum PINP monitoring may be particularly clinically
useful because this marker is relatively insensitive to food
and circadian rhythm effects, and in clinical trials, this marker
has been shown to increase dynamically in response to
teriparatide treatment [17, 18, 22–25]. The IOF and the Inter-
national Federation of Clinical Chemistry (IFCC) have recent-
ly published an extensive review of bone turnover markers
and recommend PINP as the reference biochemical marker of
bone formation [12]. Likewise, the National Bone Health
Alliance has also recommended PINP as the reference marker
for bone formation [13].
The purpose of this review is to evaluate PINP as a biolog-
ical response marker during teriparatide treatment for osteo-
porosis. A useful classification of biomarkers developed by
the Food and Drug Administration (FDA) is shown in Table 1
[26]. While some data suggest bone turnover markers might
be used in the future as a component of surrogate end points
f o r bone s t r eng th imp rovemen t s a ch i eved by
pharmacotherapeutics, more data are needed before this
Fig. 1 Type 1 collagen formation and procollagen type I N propeptide
(PINP). Type 1 procollagen is made in the osteoblast and secreted into
new bone matrix. In the bone matrix, procollagen peptidases cleave PINP
from the amino (N) terminal end and procollagen type I C propeptide
(PICP) from the carboxy (C)-terminal end of type 1 procollagen, resulting
in mature type 1 collagen. Mature type 1 collagen is the most common
protein in bone; a triple helical structure composed of two alpha-1 chains
and one alpha-2 chain. PINP and PICP make their way into the circula-
tion. Within the circulation, PINP exists as different linear forms includ-
ing the original intact trimeric PINP and the monomeric or dimeric
degradation products. Available PINP assays measure either intact triple
helical PINP or total PINP, which includes intact PINP as well as the other
forms of PINP. With permission from Bauer et al. [13]
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practice gains wide acceptance [27]. In particular, designating
PINP as a surrogate end point for fracture risk reduction is not
possible since data proving a definitive link between changes
in PINP during teriparatide treatment to fracture risk reduction
are not yet available [27]. This review will focus on PINP as a
pharmacodynamicmarker and will subsequently refer to PINP
as a biological response marker of bone formation.
Methods
Based on a review of the literature, studies involving individ-
uals treated with teriparatide 20 mcg/day by SC injection with
a measured assessment of PINP during treatment were includ-
ed for this review. This review summarizes published findings
and new and previously unpublished data, which are noted as
such.
Sample collection and logistics
Commercially available PINP assays differ by the form of
PINP they measure. The intact PINP assay measures the intact
aminoterminal propeptide form of type 1 collagen (triple
helical or trimeric), while the total PINP assay measures the
intact propeptide form (trimeric) as well as smaller monomeric
byproducts of PINP degradation [18]. Assays for measuring
intact PINP include a radioimmunoassay (RIA) for intact
PINP (UniQ™, Orion Diagnostica, Espoo, Finland) [19] and
the IDS-iSYS™ Intact PINP assay, an automated chemilumi-
nescence immunoassay (CLIA; Immunodiagnostics Systems,
Scottsdale, AZ, USA) [28]. Options for measuring total PINP
include an automated electrochemiluminescence immunoas-
say (ECLIA) for total PINP (Roche Diagnostics, Indianapolis,
IN, USA) [29] and an enzyme-linked immunosorbent assay
(ELISA) for total PINP (USCNLife Science, Inc., Houston, TX,
USA) [30, 31]. For healthy individuals, there appears to be little
difference between the results obtained for intact and total PINP
measurements [31]. However, in the presence of reduced renal
function, the clearances of intact and total PINP may differ [18].
Intact PINP relies on the liver for clearance, while the monomer-
ic form of PINP, a component of total PINP, relies on kidney
function for clearance, thereby making the interpretation of the
total PINP assays potentially difficult in the setting of kidney
disease [31, 32].
In the USA, the Orion UniQ™ PINP assay is currently the
only FDA-approved intact PINP assay [12, 19, 29, 31]. The
IDS intact PINP assay shows good agreement with the Orion
assay [28, 33, 34]. In many geographies, the Roche total PINP
assay is approved for clinical use [12]. This review includes
data demonstrating the effect of teriparatide treatment on
PINP measured by the Roche total PINP assay and by the
UniQ™ intact PINP assay. In general, the results appear to be
similar.
According to the UniQ™ kit insert, no special preparation
of the patient, such as fasting, prior to sample collection is
needed [19]. The test may be run on serum from a venous
blood sample collected by standard venipuncture technique.
After specimen collection, the blood is allowed to clot and the
serum is separated by centrifugation. Serum samples may be
stored prior to PINP analysis for up to 5 days at 2 to 8 °C and
stored for longer periods at −20 °C or lower [19]. Repeated
freezing and thawing of samples should be avoided [19].
However, different patient preparation and sample-handling
directions have also been discussed. For example, using plas-
ma samples may be preferable to serum for PINP analysis
[13].
Results
Evidence supporting PINP as a biological response marker
during teriparatide treatment
The teriparatide Phase 3 Fracture Prevention Trial
(NCT00670501) was a randomized, placebo-controlled trial
of postmenopausal women with osteoporosis and vertebral
fractures [5]. The prospectively collected biological markers
of bone formation included carboxy-terminal extension pep-
tide of procollagen type 1 (PICP) and serum bone-specific
alkaline phosphatase (bone ALP). In the teriparatide group,
PICP increased dynamically at 1 month but returned toward
baseline by 3 months [24]. The transience of PICP elevation
during teriparatide treatment suggests it is not an optimal
biological response marker. In contrast, bone ALP gradually
increased between baseline and 12 months in the teriparatide
group [24]. Yet, because bone ALP does not show dynamic
increases early during teriparatide treatment, it alsomay not be
Table 1 Categorization of biomarkers by the US Food and Drug Ad-
ministration (FDA) [26]
Biomarker category Characteristics
Prognostic biomarker Categorizes patients by probability for disease
occurrence or progression in the absence of
intervention
Predictive biomarker Categorizes patients by their probability for a
positive or negative response to a treatment
Pharmacodynamic
biomarker
Demonstrates biological response has occurred




A subset of pharmacodynamic biomarkers
Substitutes for a clinical efficacy end point and
is expected to predict clinical benefit or harm
Requires robust scientific evidence to justify
qualification as a surrogate end point
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optimal as an early biological response marker in clinical
practice.
Following completion of this trial, intact PINP was used to
measure serum PINP concentrations from samples collected
in a subset of patients at baseline and after 3 months on study
drug [24]. These samples had been stored for at least 4 years
and previously thawed at least twice prior to PINP assessment
[17]. In a subsequent analysis of these trial results, the PINP
response to teriparatide (signal) was found to be large com-
pared to the variability (noise, or fluctuation, with placebo) of
the test, as shown in Fig. 2 [17]. A relatively high signal-to-
noise ratio of PINP relative to other prospectively defined
markers of bone turnover was observed in the trial [17].
Accordingly, PINP may be particularly useful as a biological
response marker in patients treated with teriparatide.
Subsequent teriparatide clinical trials have included pro-
spectively collected PINP serum samples within their study
design. For example, in a global, randomized, double-blind
comparator trial of teriparatide vs. alendronate in 203 post-
menopausal women with osteoporosis, intact PINP was
assessed at baseline, 1, 3, 6, and 12 months of treatment
[35]. Figure 3 shows changes in PINP concentration and
urinary N-terminal cross-linking telopeptide of type I collagen
corrected for creatinine (NTX-I; biochemical marker of bone
resorption) in patients treated with teriparatide [35]. Following
initiation of teriparatide, PINP concentration increased rapid-
ly, with an increase significantly greater than baseline, and
then further increased to remain significantly above baseline
at 6 months (p<0.010) [35]. Yet, the resorption marker NTX-I
did not increase at 1 month but did increase after 3 months of
teriparatide therapy [35]. In contrast, PINP and NTX-I con-
centrations decreased markedly during alendronate treatment
[35]. Similarly, in another active comparator study of 44
postmenopausal women, PINP increased in patients treated
with teriparatide and decreased in patients treated with
risedronate, as measured by total PINP assay [36]. In addition,
another active comparator study of 79 postmenopausal wom-
en demonstrated marked increases in total PINP concentration
from baseline in women treated with teriparatide, with slight
decreases in PINP from baseline during strontium ranelate
therapy (NCT00239629) [37]. These observed changes in
serum PINP concentration are consistent with the anabolic
mechanism of action of teriparatide.
Changes in PINP concentration were evaluated during a
Phase 3 study of teriparatide conducted in Japanese men and
postmenopausal women with osteoporosis at high risk for
fracture (NCT00433160) [38]. This double-blind, placebo-
controlled trial randomized patients 2:1 to teriparatide (N=
137) or placebo (N=70) and included prospectively defined
intact PINP assessments at baseline, 1, 3, 6, and 12 months of
treatment. Fig. 4 shows the effects of teriparatide vs. placebo
on median PINP concentrations in this study population [39].
These changes in serum PINP concentration were significant-
ly different at 1, 3, 6, and 12 months (p<0.001) [39]. The
sharpest rise in PINP concentration occurred within the first
month of teriparatide treatment [39].
Patients treated with teriparatide may have been treated
previously with antiresorptive drugs and switched to
Signal-to-Noise Ratio, 3 months






Fig. 2 Signal-to-noise ratio for biological markers of bone turnover
measured at 3 months in the Fracture Prevention Trial of postmenopausal
women with osteoporosis. Bone turnover markers other than PINP were
measured in a subset of 171 women in the teriparatide 20 mcg/day group
and 175 women in the placebo group. PINP was measured in a subset of
254 women in the teriparatide 20 mcg/day group and 260 women in the
placebo group from samples that had been stored frozen for at least
4 years and had been previously thawed at least twice [17]. DPD urinary
deoxypyridine corrected for creatinine, NTX-I urinary N-terminal cross-
linking telopeptide of type I collagen corrected for creatinine, Bone ALP
bone alkaline phosphatase, PICP procollagen type I C propeptide, PINP
intact procollagen type I N propeptide. Adapted from Eastell and col-
leagues [17]
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teriparatide. In the EUROFORS study, 758 postmenopausal
women with osteoporosis who were either treatment-naive,
previously treated with an antiresorptive, or who had failed
antiresorptive treatments were all given teriparatide
(NCT00191425) [40, 41]. Samples for PINP assessment were
prospectively collected at baseline, 1, and 6 months and
analyzed by total PINP [41]. As expected, baseline PINP
was significantly lower in the previous antiresorptive groups
than the treatment-naive group. PINP increased from baseline
in all treatment groups, with significantly greater increases
noted in the treatment-naive group than the previous
antiresorptive groups at 1 month. However, there were no
significant differences in PINP concentrations between the
treatment-naive and the previous antiresorptive groups at
6 months [40, 41]. Overall, teriparatide increased biochemical
markers of bone formation in postmenopausal women with
established osteoporosis, regardless of previous long-term
exposure to antiresorptive therapies [40, 41].
PINP was also evaluated in a prospective, open-label,
nonrandomized study of 59 postmenopausal women with
osteoporosis previously treated with raloxifene or with
alendronate for at least 18 months, and then switched to
teriparatide [42]. Intact PINP assessments were prospectively
collected at baseline, 1, 3, 6, and 12 months of teriparatide
treatment. Consistent with alendronate being a more potent
inhibitor of bone turnover than raloxifene, baseline PINP
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Fig. 3 Typical effects of
teriparatide on bone formation
and bone resorption markers
during teriparatide treatment in
postmenopausal women with
osteoporosis. Percentage change
(adjusted least squares mean±
standard error) from baseline in
serum PINP and urinary NTX-I in
patients treated with teriparatide.
PINP intact procollagen type I N
propeptide, NTX-I urinary N-
terminal cross-linking
telopeptide of type I collagen
corrected for creatinine.
*p<0.001, **p<0.050 for change
from baseline within-group
comparisons. Adapted from
McClung and colleagues [35]
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Fig. 4 Changes in intact PINP in
a trial of Japanese patients with
osteoporosis randomized to
teriparatide or to placebo. Median
change from baseline in PINP.
PINP intact procollagen type I N
propeptide, IQR interquartile
range. *p<0.001for within-group
comparisons. The I-bars represent
interquartile ranges (25th, 75th
percentile). Adapted from
Tsujimoto and colleagues [39]
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concentrations were lower in the alendronate group compared
with the raloxifene group. During the treatment with
teriparatide, statistically significant increases in PINP concen-
tration from baseline occurred in both groups, but with a
significantly smaller increase in the first month observed in
the alendronate group than in the raloxifene group. No statis-
tically significant difference between treatment groups oc-
curred at subsequent time points [42]. This study included
serial osteocalcin assessments. During teriparatide treatment,
this marker shows changes similar to those of PINP.
In another study of patients with prior bisphosphonate
exposure (alendronate, risedronate, etidronate, or
pamidronate), total PINP was lower at baseline (p=0.010),
at 3 months, and at 6 months during teriparatide treatment in
38 patients with prior bisphosphonate exposure compared
with 14 patients without prior bisphosphonate exposure [43].
These findings suggest that previous treatment with the potent
antiresorptive drug alendronate appears to delay the PINP
response to teriparatide, but with continued teriparatide treat-
ment, PINP increases are observed [42, 43].
PINP response to teriparatide may be impacted differently
by different bisphosphonates. For example, in the
OPTAMIZE study, patients treated with alendronate or
risedronate for at least 24months were switched to teriparatide
for 12 months of treatment. In the prior risedronate group, the
PINP increase was significantly greater after 3 months of
teriparat ide than in the prior alendronate group
(NCT00130403) [44].
An open-label study of 137 osteoporosis drug-naive post-
menopausal women with osteoporosis, randomized to treat-
ment with either teriparatide alone or to teriparatide plus
raloxifene, evaluated intact PINP at baseline, 1, 3, and
6 months of treatment to determine the effect of the concom-
itant use of teriparatide with raloxifene on serum PINP con-
centration (NCT00046137) [45]. PINP significantly increased
in both treatment groups similarly, demonstrating concomitant
use of teriparatide with raloxifene resulted in a typical anabol-
ic PINP response [45].
In regard to concomitant use of teriparatide with
alendronate or with raloxifene, a prospective, open-label study
of 198 postmenopausal women, with osteoporosis who were
previously treated with raloxifene or alendronate for at least
18 months, randomized patients to add teriparatide and con-
tinue their antiresorptive drugs or to switch to teriparatide
alone (“add” vs. “switch”) (NCT00079924) [46]. Total PINP
assessments were prospectively collected at baseline, 1, 3, 6,
12, and 18 months of treatment. In all groups, PINP increased
significantly from baseline during teriparatide treatment.
However, the increases were smaller in the groups that added
teriparatide to ongoing antiresorptive therapy compared with
the groups that switched to teriparatide. In the alendronate
stratum at 6 months, median PINP increases from baseline
were 64 % vs. 401 % (p<0.001) in the add vs. switch groups,
respectively. In the raloxifene stratum at 6 months, median
PINP increases from baseline were 131 % vs. 259 %
(p<0.001) in the add vs. switch groups, respectively [46].
These differences in PINP for add vs. switch groups demon-
strate relatively greater bone formation with the switch ap-
proach, although the switch approach was also associated with
greater bone resorption [46].
PINP monitoring may also find application in the manage-
ment of patients with glucocorticoid-induced osteoporosis.
For patients treated with chronic systemic glucocorticoids,
the skeletal defect at the tissue level is impaired bone forma-
tion [47]. In a randomized, double-blind, active comparator
trial of 428 men and women with glucocorticoid-induced
osteoporosis (prednisone equivalent 5 mg/day or more for at
least 3 months and BMD T-score at spine or hip of −2 or less,
or −1 plus a history of a fragility fracture), intact PINP assess-
ments were prospectively collected at baseline, 1, 6, and
18 months of treatment with teriparatide or alendronate
(NCT00051558) [48–52]. In the teriparatide group, PINP
concentration was significantly increased (p<0.001) by
1 month and peaked at 6 months, with an observed median
69.8 % increase [48]. Notably, PINP concentrations remained
above baseline during the 36 months of treatment [49].
From the same glucocorticoid-induced osteoporosis trial,
PINP data for 83 male patients have been reported. Intact
PINP serum concentration increased significantly during
teriparatide treatment, peaked at 1 to 6 months, and remained
above baseline at 18 months [51]. In another study of
glucocorticoid-induced osteoporosis in 92 men, the typical
expected increase in intact PINP during teriparatide treatment
was observed, which was statistically significant as compared
with risedronate (p<0.001) [53]. These results confirm an
increase in PINP can be expected in males with
glucocorticoid-induced osteoporosis treated with teriparatide
(NCT00503399) [53].
Also from the glucocorticoid-induced osteoporosis trial
described above, PINP data for 67 premenopausal women
have been reported (NCT00051558) [53]. During treatment
with teriparatide, PINP increased from baseline at all time
points, with peak increases observed at 1 to 6 months [53].
Similarly, increases in PINP were also noted in a study of 21
premenopausal women with unexplained fragility fractures or
low BMD treated with teriparatide (NCT01440803) [54].
Serum PINP increased at 1 month, was 150 % above baseline
at 6 months, and declined toward baseline at 18- and 24-
month assessments [54]. These results confirm an increase
in PINP can be expected in premenopausal females treated
with teriparatide.
The early onset of PINP response to teriparatide was
assessed in 15 osteopenic postmenopausal women treated
with daily SC teriparatide 20 mcg/day [55]. Intact PINP
concentrations increased by 8.2 % after 2 days of treatment
and by 111 % after 28 days of teriparatide treatment, with all
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observed PINP increases significant compared with baseline
(p<0.0001) [55]. This study showed approximately similar
increases in PINP, PICP, and osteocalcin during 28 days of
teriparatide treatment, but showed a smaller increase in bone
ALP [55]. Following cessation of treatment at 28 days, con-
centrations of bone formation markers decreased to within
20 % of baseline values by day 56 [55].
Relationship of PINP concentration to bone formation
during teriparatide treatment
A Phase 4 clinical trial of ten postmenopausal women with
osteoporosis treated with teriparatide showed a typical in-
crease in intact PINP (NCT00259298) [56]. Increase from
baseline in serum PINP concentrations at 3 and 18 months
of treatment were correlated with an increase from baseline in
skeletal uptake of radiopharmaceutical technetium-99 m
methylene diphosphonate on a bone scan at the same visit
(r=0.60 at 3 months, r=0.78 at 18 months) [56].
In an active comparator study of 69 postmenopausal wom-
en with osteoporosis, those patients treated with teriparatide
again showed a typical increase in intact PINP
(NCT00927186) [57]. Additionally, the correlation between
6-month PINP concentration and bone formation, defined by
the mineralizing surface of trans-iliac bone biopsies, was high
(r=0.85), confirming PINP concentration is related to bone
formation at the bone tissue level [57]. These data demonstrate
PINP concentration is strongly related to skeletal bone forma-
tion as assessed by bone scan and by trans-iliac bone biopsy.
Relationship of early change in PINP concentration
to other outcomes during teriparatide treatment
Several teriparatide studies have shown statistically signifi-
cant correlations between an early change in PINP concentra-
tion and a later increase in BMD during teriparatide treatment
[22, 23, 35, 39, 40, 57, 58]. In general, the best correlations
were obtained between change in PINP concentration at
1 month and later percent increase in lumbar spine BMD.
For example, the relationship between the 1-month change in
PINP vs. 12-month percent change in lumbar spine BMD is
shown in Fig. 5 [39]. Note that nearly complete separation of
patients treated with teriparatide from patients treated with
placebo was achievedwith these biomarkers. Using Spearman
correlation analysis, the highest correlation coefficient value
between the bone turnover marker and BMD response was
observed between the change in PINP concentration at 1-
month and the 12-month lumbar spine BMD percent change
(r=0.76; p<0.010) [39]. These data support early increases in
bone formation during teriparatide treatment, reflected by
increases in PINP concentration, predict later increases in
BMD.
Teriparatide studies have shown statistically significant
correlations between early PINP change and later percent
increases in bone strength at the spine as determined by finite
element analysis. In the teriparatide vs. alendronate active
comparator study described above, postmenopausal women
with osteoporosis were randomized to teriparatide 20mcg/day
or alendronate 10 mg/day in a double-blind fashion [35].
Quantitative computed tomography scans with finite element
modeling of the L3 vertebra were performed in a subset of 21
teriparatide patients at baseline and 18 months [4]. Pearson
correlation coefficients were calculated for log-transformed
changes from baseline in biochemical markers of bone turn-
over at various times and compared with changes from base-
line in vertebral strength parameters at 18 months. The best
predictor of 18-month vertebral strength increases was PINP
increments at 1 month in teriparatide-treated patients. The
correlation coefficients for vertebral compressive stiffness
and volumetric BMD were 0.45 and 0.51, respectively, with
p values <0.05 [4, 23]. In another study, 1- and 3-month total
PINP increases vs. baseline were similarly correlated with 18-
month percent increase in spine strength as assessed by finite
element analysis in four different groups (NCT 00079924)
[46]. Additional analysis of the correlation between increases
in PINP and bone strength was reported in males with
glucocorticoid-induced osteoporosis [52]. In this study,
changes in intact PINP at 3 months were correlated with
change in finite element analysis strength increments in the
spine to anterior bending (r=0.422), axial compression (r=
0.516), and axial torsion (r=0.496) assessed at 6 and
18 months of treatment [52]. These findings support a corre-
lation between early changes in serum PINP and later in-
creases in spine BMD and strength in patients treated with
teriparatide.
Data to fully assess the relationship of early PINP change
with fracture risk reduction are not available, since the large
Phase 3 teriparatide fracture trial included PINP assessments
in only a subset of the patients [22, 23]. However, the signif-
icant relationship between early change in PINP and later
increase in BMD described above, along with the significant
relationship between increase in BMD and fracture risk re-
duction during teriparatide treatment [24], provide indirect
evidence for a relationship between PINP change and fracture
risk reduction.
In the randomized, double-blind, active comparator trial of
428 men and women with glucocorticoid-induced osteoporo-
sis described above, there was a significant reduction in ver-
tebral fracture in the teriparatide vs. alendronate group [48,
49]. A subset of patients from both treatment groups in the
trial had PINP assessments. The incidence of vertebral frac-
tures in the subset of patients with PINP assessments was
similar to the incidence of vertebral fractures in the overall
study population (Fig 6). Because most patients in the
teriparatide group had increases in PINP>10 mcg/L and most
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patients in the alendronate group did not, the incidence of
vertebral fractures in the subgroup of patients with vs. without
PINP increase from baseline >10 mcg/L was also similar to
the overall incidence (Fig. 6).
PINP response in individual patients
The intact PINP assay label references a least significant
change (LSC) for PINP of 21 % [19, 59]. However, this
21 % definition of LSC for PINP during teriparatide treatment
is problematic because many patients treated with teriparatide
have been previously treated with potent antiresorptive drugs
such as alendronate, and as noted above, these patients often
have a relatively low baseline PINP concentration. For exam-
ple, a typical patient treated with alendronate might have a
baseline intact serum PINP concentration of 19 mcg/L. In
such a patient, use of the 21 % cut point (LSC) would lead
to the conclusion that an increase in PINP to 23mcg/L (a 21%
increase from baseline) represents a significant increase in
PINP even though this is obviously a small increment and
below what would be considered a meaningful change. To
overcome this difficulty, Eastell and colleagues established an
absolute change cut point by using the typical mean PINP
concentration of 48mcg/L in untreated postmenopausal wom-
en [19] and multiplying the value by 0.21 (LSC) to arrive at a
LSC of >10 mcg/L [17]. Absolute change in PINP is simple to
calculate and is not subject to the percentage difficulties that
arise in patients with very low baseline PINP concentrations
[17]. Eastell and colleagues [17] proposed an algorithm for
using the observed change in PINP serum concentration to
monitor patients treated with teriparatide. This algorithm was
tested and slightly modified by Krege and colleagues [60] and
then evaluated in detail once again by Tsujimoto and col-
leagues [39]. An illustration of this simplified approach to
using serum PINP concentration to monitor patients treated
with teriparatide is provided in Fig. 7.
A prospective Phase 3, double-blind, placebo-controlled
clinical trial included prospectively defined intact PINP anal-
yses at baseline, 1, 3, 6, and 12months to assess response rates
in individuals treated with placebo or teriparatide [38, 39]
(NCT00433160). In the placebo group, 2 out of 66 patients
Change From Baseline to 1 Month in 
Serum PINP Concentration (mcg/L)

























Fig. 5 Correlation between
procollagen type I N propeptide
(PINP) change from baseline to
1 month (mcg/L) and percent
change in lumbar spine bone
mineral density (BMD) from
baseline to 12 months in a trial of
Japanese patients with
osteoporosis randomized to
teriparatide or to placebo. A
vertical line represents a PINP
increase of 10 mcg/L, and a
horizontal line represents a
lumbar spine BMD increase of
3 %. Adapted from Tsujimoto and
colleagues [39]
Fig. 6 Vertebral fracture outcomes at 36 months from a trial of gluco-
corticoid-induced osteoporosis patients randomized to alendronate or to
teriparatide. The left side of the figure represents data by treatment group
assignment. The right side of the figure represents data for a subset of
patients (N=199)who had PINP assessments at baseline, 1, and 6months,
designating PINP increment from baseline >10 mcg/L at 1 or 6 months.
TPTD teriparatide, ALN alendronate, PINP intact procollagen type I N
propeptide. Adapted from Saag and colleagues [49]
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had PINP increases >10 mcg/L at 1 or 3 months, indicating a
false-positive rate of 3 % when employing the monitoring
algorithm. Among the 136 patients in the teriparatide
20 mcg/day group, 129 patients had PINP increases
> 10 mcg/L at 1 or 3 months, and 7 patients did not. Among
these seven patients, three were noncompliant and four were
compliant. The absence of an increase in PINP > 10 mcg/L at
1 or 3 months in 4 out of 136 compliant patients indicates a
false-negative rate of 3 % when using the monitoring algo-
rithm [39]. Table 2 summarizes the findings from Tsujimoto
and colleagues [39], defining a significant increase in PINP as
an increase > 10 mcg/L at 1 or 3 months and a significant
increase in lumbar spine BMD as an increase > 3 % at
12 months. These results demonstrate that clinically useful
complementary information may potentially be gained from
monitoring both PINP and BMD during osteoanabolic
therapy.
Defining significant responses in this samemanner, Table 3
presents potential patient observations and health care profes-
sional responses illustrating the potential use of PINP moni-
toring to enhance teriparatide therapy for individual patients.
PINP response during teriparatide therapy has been evalu-
ated in additional clinical trials in which PINPmonitoring was
prospectively defined [7, 17, 56]. In drug-naive postmeno-
pausal women with osteoporosis, the proportion of patients
with increases in intact PINP > 10mcg/L was 85% at 1 month
and 87 % at 3 months [17]. In postmenopausal women with
osteoporosis previously treated with raloxifene for at least
18 months and then switched to teriparatide, the proportion
of patients with increases in intact PINP > 10 mcg/L was 96 %
at 1 month and was 92 % at 3 months [17]. Yet, in postmen-
opausal women with osteoporosis previously treated with
alendronate for at least 18 months and then switched to
teriparatide, the proportion of patients with increases in intact
PINP > 10 mcg/L was 79 % at 1 month and was 97 % at
3 months [17]. The observed delay in the rise of serum PINP
concentration for the teriparatide group previously treated with
alendronate may be a result of the prior potent antiresorptive
therapy.
PINP response to teriparatide following previous therapies,
with concurrent therapies, or with concomitant illnesses
Clinical study data provide insight into the effect of prior
osteoporosis drug treatment on PINP response during
teriparatide treatment. For example, the EUROFORS study
included three osteoporosis treatment cohorts: (1) treatment-
naive patients, (2) patients pretreated with antiresorptive
drugs, and (3) patients pretreated with antiresorptive drugs
with inadequate clinical outcome [40, 41]. Total PINP re-
sponses > 10 mcg/L were similar in these groups [60]. Over-
all, the percentage of patients achieving a PINP increase
> 10 mcg/L in the EUROFORS study was 83 % (613/736)
at 1 month and 91 % (630/689) at 6 months [60]. Among the
110 patients with 1-month PINP increases ≤10 mcg/L, 88
(80 %) had 6-month PINP increases > 10 mcg/l [60].
PINP response to teriparatide in patients treated with other
concomitant osteoporosis medications was evaluated in a
recent clinical trial including patients previously treated for
at least 18 months with alendronate or raloxifene
(NCT000799924) [61]. These patients were randomized ei-
ther to switch to teriparatide or to add teriparatide to ongoing
alendronate or raloxifene [61]. Defining a PINP response as
an intact PINP increment > 10 mcg/L at 1 or 3 months, the
response rates (previously unpublished data) are shown in
Table 4 [61].
A study of the combination of teriparatide plus denosumab
has recently been published [62]. With this treatment
Biological response detected
Suggests patient may be 
taking teriparatide correctly
Encourage continuation 





PINP increase >10 mcg/L
PINP increase 10 mcg/L
Biological response not detected
Review injection technique,
storage, adherence, and 
potential medical problems 
limiting response
Fig. 7 Simplified approach to using PINP to assess osteoporosis patients
treated with teriparatide. PINP is a biological response marker indicating
whether bone formation has increased between baseline and follow-up
measurements in a patient treated with teriparatide. A biological response
marker is not a surrogate marker of efficacy, which would predict future
outcomes like fracture. PINP intact procollagen type I N propeptide
Table 2 Response of PINP and BMD during osteoanabolic therapy [39]
Treatment group PINP respondera BMD responderb
Teriparatide 95 % 94 %
Placebo 3 % 20 %
BMD bone mineral density, PINP procollagen type I N propeptide
a >10 mcg/L increase in serum PINP concentration at 1 or 3 months
b >3 % increase in BMD at 12 months
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combination, intact PINP does not appear to increase, but
rather PINP shows a significant decrease from baseline. This
study suggests that an increase in PINP should not be antici-
pated to occur with combination teriparatide plus denosumab
treatment [62].
PINP response to teriparatide in patients with other chronic
medical illnesses has been evaluated. PINP was collected in a
randomized, double-blind trial of men and women with
glucocorticoid-induced osteoporosis (NCT00051558)
[47–49]. These individuals had various baseline conditions
for which they were treated with glucocorticoids including
rheumatoid arthritis, systemic lupus erythematosis,
polymyalgia rheumatica, vasculitis, respiratory disorders,
and inflammatory bowel disease. In these medically complex
individuals treated with teriparatide, glucocorticoids, and a
variety of other concomitant medications, the proportion of
individuals with increases in intact PINP > 10 mcg/L at 1 or
6 months was 88 % [63].
Discussion
As highlighted in this review, PINP may be most useful as a
biological response marker. In clinical trials, PINP testing
usually detects a biological response to teriparatide treatment
and a lack of biological response to placebo. While the data
provided in this review are, in general, supportive that an
increase in PINP during teriparatide treatment is associated
with increases in BMD and bone strength, increases in PINP
during teriparatide treatment have not been directly validated
to predict fracture risk reduction. This proof is not yet avail-
able because PINP monitoring was only performed on stored
samples from a subset of patients enrolled in the Phase 3
teriparatide fracture trial [17].
Using PINP as a biological response marker during
teriparatide treatment for osteoporosis has some limitations.
Results of the PINP assay should be used in conjunction with
other pertinent clinical information to make diagnostic and
therapeutic decisions.Most importantly, PINP testing does not
replace BMD testing. Rather, as highlighted in this review, the
results of PINP monitoring may be complementary to those of
BMD testing [11, 27, 64]. The PINP assay is not recommend-
ed for use as a screening procedure to detect the presence of
osteoporosis in the general population [19]. And, as yet, the
evidence base that biochemical markers of bone turnover can
be used in the assessment of fracture risk in individual patients
is limited [17, 27]. There is a chance for both false-positive
and false-negative results with all laboratory tests, and this is a
potential limitation with PINP testing. The clinical trials
reviewed herein have demonstrated that a majority of, but
not all, patients taking teriparatide will have an increase in
PINP concentration from baseline, and PINP may increase in
some patients taking placebo. This problem might be more of
an issue in clinical practice than in the setting of clinical trials.
To reduce variability of PINP assessments in clinical practice,
Table 3 Hypothetical clinical scenarios, with potential clinical responses, and relevant data from Tsujimoto and colleagues [39]
Hypothetical clinical scenario Hypothetical clinical response Data to support clinical response [39]
No increase in PINP, patient not taking
teriparatide or not storing or injecting
the medication properly
Patient provided assistance to acquire
teriparatide or education regarding
storage and administration
In the placebo group, 97 % of patients had no significant PINP
response. In the teriparatide group, three noncompliant
patients had no significant PINP response.
Increase in PINP, patient taking
teriparatide according to label
Patient encouraged to continue with therapy In the teriparatide group, 95 % had significant PINP response
(a total of seven patients had no significant PINP response,
with three of these patients not being compliant with
treatment).
No increase in PINP, patient taking
teriparatide properly, no early increase
in BMD
Patient switched to alternative treatment In the teriparatide group, one compliant patient had no
significant PINP or lumbar spine BMD response and was a
nonresponder.
No increase in PINP, injecting and storing
teriparatide properly, BMD increases
Patient encouraged to continue with therapy In the teriparatide group, three patients with PINP increases of
5, 9, and 10 μg/l had significant lumbar spine BMD
responses at 6 months.
These scenarios assume that a baseline and post-teriparatide treatment PINP sample is obtained. A significant increase in PINPwas defined as an increase
from baseline in PINP>10 mcg/L at 1 or 3 months, and a significant increase in lumbar spine BMD was defined as an increase from baseline>3 %
BMD bone mineral density, PINP procollagen type I N propeptide
Table 4 PINP response by treatment group in Cosman and colleagues
[61]
Treatment group PINP responsea, N (%)
Alendronate plus teriparatide 40/52 (77 %)
Raloxifene plus teriparatide 45/47 (96 %)
Switched from alendronate or raloxifene
to teriparatide
97/99 (98 %)
PINP procollagen type I N propeptide
a PINP increment>10 mcg/L at 1 or 3 months
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it might be possible to store the baseline sample at −20°C [19]
and to run the baseline and follow-up serum sample as a batch.
As yet, the evidence for use of biochemical markers as a
tool to improve adherence with treatment is weak. For exam-
ple, a study of 596 patients treated with monthly ibandronate
examined the impact of serum C-terminal cross-linking
telopeptide of type I collagen (CTX-1, a biochemical marker
of bone resorption) monitoring and feedback on patient ad-
herence [65]. The results were similar among the groups
whether they received biochemical marker feedback or not,
with adherence documented in 92.6 % of patients given feed-
back and 96 % of patients not given feedback [65]. However,
as noted in this particular trial, participants in clinical trials
tend to have such high adherence that improvements may be
difficult to document. Also, while this study showed no dif-
ference in adherence, patients provided with information
about their biochemical markers of bone turnover felt more
informed about their osteoporosis (p<0.001) and more satis-
fied (p<0.010) than those patients not provided with informa-
tion [65]. Whether testing of biochemical markers of bone
turnover may improve adherence outside of the setting of
clinical studies is not yet known.
In the clinical setting, biochemical markers of bone turn-
over may be elevated for some months after a fracture event
and during the fracture healing process [66]. Some of the
studies in this review included many patients with previous
fracture [24, 58] and demonstrated correlations between early
increases in PINP and later increases in BMD. Accordingly, it
is possible that a recent fracture does not preclude a typical
PINP response to teriparatide treatment. The question of the
effect of recent fracture on the PINP response to teriparatide
could potentially be addressed through post hoc analyses of
appropriate clinical trials.
The IOF, the IFCC, and the National Bone and Health
Alliance recommend a number of measures for optimizing
the clinical use of PINP monitoring in the day-to-day care of
patients with osteoporosis [12, 13, 67]. In addition to the
importance of harmonization for future research of bone turn-
over markers, these groups recommend the standardization of
bone marker sample collection procedures, reference ranges,
and bone turnover marker assays in clinical laboratories [12,
13, 67, 68]. Toward this end, preliminary data from an exter-
nal quality assurance scheme suggest that the three major
serum PINP assays provide harmonized results [68]. Howev-
er, as previously discussed, total PINP provides higher values
than intact PINP in the setting of impaired renal function [31,
32].
In summary, PINP is a product of the processing of type I
procollagen to mature type I collagen, the most prevalent
protein in the bone [19]. Quantifying PINP measures anabolic
activity in the bone. Depending on geography, serum assays
for measuring PINP concentration are available and approved
to aid in the management of patients with postmenopausal
osteoporosis. Based on advantages of PINP monitoring and
extensive literature regarding the effects of various therapeutic
agents on concentrations of PINP, the PINP test is recom-
mended as the reference biochemical marker of bone forma-
tion by the IOF, IFCC, and the National Bone Health Alliance.
Substantial evidence from clinical trials demonstrates PINP is
a biological response marker that increases rapidly and dy-
namically in most teriparatide-treated patients and does not
increase in most placebo-treated patients. A biological re-
sponse to anabolic osteoporosis therapy may be defined as
an increase in PINP concentration > 10 mcg/L from baseline.
PINP monitoring may be useful for clinicians prescribing
teriparatide for osteoporosis patients at high risk for fracture.
Data validating the use of PINP for predicting fracture risk
reduction during teriparatide treatment are not available.
PINP testing has the potential to support patients taking
teriparatide as prescribed, and thereby maximize their chances
for clinical benefit and positive treatment outcome.
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